Adequate Information. The Investor has received from the Issuer, and has reviewed, such information which the Investor considers necessary or appropriate to evaluate the risks and merits of an investment in the Shares. The Investor also acknowledges that the additional risk factors set forth on Exhibit D and contained in the SEC Reports are specifically incorporated herein by reference and form an integral part of this Agreement.
Appears in 2 contracts
Samples: Subscription Agreement (Regen Biologics Inc), Subscription Agreement (Regen Biologics Inc)
Adequate Information. The Investor has received from the Issuer, and has reviewedhad the opportunity to review, such information which the Investor considers necessary or appropriate to evaluate the risks and merits of an investment in the SharesNotes. The Investor also acknowledges that the additional risk factors set forth on Exhibit D and contained in the SEC Reports are specifically incorporated herein by reference have been delivered to the Investor and form an integral part of this Agreementthe Investor has had the opportunity to review such risk factors.
Appears in 2 contracts
Samples: Subscription Agreement (Regen Biologics Inc), Subscription Agreement (Regen Biologics Inc)
Adequate Information. The Investor has received from the Issuer, and has reviewedhad the opportunity to review, such information which the Investor considers necessary or appropriate to evaluate the risks and merits of an investment in the SharesShares and Warrants. The Investor also acknowledges that the additional risk factors set forth on Exhibit D C and contained in the SEC Reports are specifically incorporated herein by reference have been delivered to the Investor and form an integral part of this Agreementthe Investor has had the opportunity to review such risk factors.
Appears in 2 contracts
Samples: Subscription Agreement (Regen Biologics Inc), Subscription Agreement (Regen Biologics Inc)
Adequate Information. The Investor has received from the Issuer, and has reviewed, such information which the Investor considers necessary or appropriate to evaluate the risks and merits of an investment in the SharesShares and Warrants. The Investor also acknowledges that the additional risk factors set forth on Exhibit D B and contained in the SEC Reports are specifically incorporated herein by reference and form an integral part of this Agreement.
Appears in 2 contracts
Samples: Subscription Agreement (Regen Biologics Inc), Subscription Agreement (Regen Biologics Inc)
Adequate Information. The Investor has received from the Issuer, and has reviewedhad the opportunity to review, such information which the Investor considers necessary or appropriate to evaluate the risks and merits of an investment in the SharesNotes. The Investor also acknowledges that the additional risk factors set forth on Exhibit D C and contained in the SEC Reports are specifically incorporated herein by reference have been delivered to the Investor and form an integral part of this Agreementthe Investor has had the opportunity to review such risk factors.
Appears in 1 contract
Adequate Information. The Investor has received from the Issuer, and has reviewed, such information which the Investor considers necessary or appropriate to evaluate the risks and merits of an investment in the Shares. The Investor also acknowledges that the additional risk factors set forth on Exhibit D C and contained in the SEC Reports are specifically incorporated herein by reference and form an integral part of this Agreement.
Appears in 1 contract